Phase 2 N=102 Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI
Spinal Cord Injuries
Primary: American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up — 183.88 score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
Atopic Dermatitis
Primary: Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4 — 14.93; 22.39; 9.09 percentage of participants
Phase 2 N=101 Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Multiple Myeloma
Primary: Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product — 71; 46; 1; 4 Participants
Phase 2 N=20 Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients
Atrial Fibrillation · Lung Transplant; Complications
Primary: Post Operative Atrial Fibrillation — 6 Participants
Phase 2 N=24 A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Menopause · Multiple Sclerosis
Primary: Hot Flash Related Daily Interference Scale (HFRDIS) Score — 4; 9 score on a scale
Phase 2 N=32 Ketoconazole and Dexamethasone in Prostate Cancer
Prostate Cancer
Primary: Number of Participants Who Achieved a Second Decline in Prostate Specific Antigen (PSA) Following Progression on First Regimen — 0 Participants
Phase 2 N=304 A Study of LY2623091 in Participants With High Blood Pressure
Primary Hypertension
Primary: Change From Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP) — -0.5; -13.1; -14.6; -14.3 millimeter of mercury (mmHg)
Phase 2 N=37 Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Refractory Diffuse Large B Cell Lymphoma
Primary: Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 1 Participants
Phase 2 N=23 An Open Label Study of Oral Enzastaurin in Participants With Cancer
Neoplasms · Cancer
Primary: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 19; 9 Participants
Phase 2 N=33 A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects
Constipation
Primary: Treatment Response — 32 Participants
Phase 2 N=8 Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
Hypercholesteremia
Primary: Percent Change From Baseline in LDL-C at Day 28 — -25.54 Percent Change — p=0.0041
Phase 2 N=105 A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
Hypercholesteremia
Primary: Percent Change From Baseline in LDL-C at Week 12 — -16.03; -4.98 Percent Change — p=0.0057
Phase 2 N=91 A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia · Mixed Dyslipidaemia
Primary: Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG) — -47.32; -32.95; -27.30 Percent Change — p=0.0063
Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Phase 2 N=80 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Mediastinal Large B-cell Lymphoma · Richter Syndrome
Primary: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review — 45.3; 13.0 Percentage of…